Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines

Research output: Contribution to journalArticle

Abstract

In preclinical models, tumor cells genetically altered to secrete cytokines or express costimulatory molecules can generate systemic antitumor immunity. In some studies, these tumor vaccines have been shown to eradicate micro-metastases. These results have led to the initiation of numerous phase I clinical trials employing either genetically modified or allogenic tumor vaccines. This article addresses a number of issues related to the clinical development of cytokine gene-transduced tumor cell vaccines including: (1) the production of cytokine-secreting tumor vaccines; and (2) the preclinical feasibility and toxicity studies required for testing these vaccines in patients with cancer.

Original languageEnglish (US)
Pages (from-to)143-153
Number of pages11
JournalMethods in Enzymology
Volume12
Issue number2
DOIs
StatePublished - Jun 1997

Fingerprint

Cancer Vaccines
Tumors
Vaccines
Genes
Cells
Cytokines
Clinical Trials, Phase I
Toxicity
Feasibility Studies
Immunity
Neoplasms
Molecules
Testing
Neoplasm Metastasis

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{7510dd2653d04207b550f912d8f47f39,
title = "Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines",
abstract = "In preclinical models, tumor cells genetically altered to secrete cytokines or express costimulatory molecules can generate systemic antitumor immunity. In some studies, these tumor vaccines have been shown to eradicate micro-metastases. These results have led to the initiation of numerous phase I clinical trials employing either genetically modified or allogenic tumor vaccines. This article addresses a number of issues related to the clinical development of cytokine gene-transduced tumor cell vaccines including: (1) the production of cytokine-secreting tumor vaccines; and (2) the preclinical feasibility and toxicity studies required for testing these vaccines in patients with cancer.",
author = "Elizabeth Jaffee and Pardoll, {Andrew Mark}",
year = "1997",
month = "6",
doi = "10.1006/meth.1997.0463",
language = "English (US)",
volume = "12",
pages = "143--153",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines

AU - Jaffee, Elizabeth

AU - Pardoll, Andrew Mark

PY - 1997/6

Y1 - 1997/6

N2 - In preclinical models, tumor cells genetically altered to secrete cytokines or express costimulatory molecules can generate systemic antitumor immunity. In some studies, these tumor vaccines have been shown to eradicate micro-metastases. These results have led to the initiation of numerous phase I clinical trials employing either genetically modified or allogenic tumor vaccines. This article addresses a number of issues related to the clinical development of cytokine gene-transduced tumor cell vaccines including: (1) the production of cytokine-secreting tumor vaccines; and (2) the preclinical feasibility and toxicity studies required for testing these vaccines in patients with cancer.

AB - In preclinical models, tumor cells genetically altered to secrete cytokines or express costimulatory molecules can generate systemic antitumor immunity. In some studies, these tumor vaccines have been shown to eradicate micro-metastases. These results have led to the initiation of numerous phase I clinical trials employing either genetically modified or allogenic tumor vaccines. This article addresses a number of issues related to the clinical development of cytokine gene-transduced tumor cell vaccines including: (1) the production of cytokine-secreting tumor vaccines; and (2) the preclinical feasibility and toxicity studies required for testing these vaccines in patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031172693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031172693&partnerID=8YFLogxK

U2 - 10.1006/meth.1997.0463

DO - 10.1006/meth.1997.0463

M3 - Article

C2 - 9184378

AN - SCOPUS:0031172693

VL - 12

SP - 143

EP - 153

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - 2

ER -